HELIX BIOPHARMA Financials
| HBP Stock | EUR 1.15 0.00 0.00% |
HELIX |
Understanding current and past HELIX BIOPHARMA Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of HELIX BIOPHARMA's financial statements are interrelated, with each one affecting the others. For example, an increase in HELIX BIOPHARMA's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in HELIX BIOPHARMA's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of HELIX BIOPHARMA. Check HELIX BIOPHARMA's Beneish M Score to see the likelihood of HELIX BIOPHARMA's management manipulating its earnings.
You should never invest in HELIX BIOPHARMA without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of HELIX Stock, because this is throwing your money away. Analyzing the key information contained in HELIX BIOPHARMA's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
HELIX BIOPHARMA Key Financial Ratios
HELIX BIOPHARMA's financial ratios allow both analysts and investors to convert raw data from HELIX BIOPHARMA's financial statements into concise, actionable information that can be used to evaluate the performance of HELIX BIOPHARMA over time and compare it to other companies across industries.HELIX Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HELIX BIOPHARMA's current stock value. Our valuation model uses many indicators to compare HELIX BIOPHARMA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HELIX BIOPHARMA competition to find correlations between indicators driving HELIX BIOPHARMA's intrinsic value. More Info.HELIX BIOPHARMA is rated as one of the top companies in current valuation category among its peers. It also is one of the top stocks in price to book category among its peers . The ratio of Current Valuation to Price To Book for HELIX BIOPHARMA is about 572,489 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HELIX BIOPHARMA's earnings, one of the primary drivers of an investment's value.HELIX BIOPHARMA Systematic Risk
HELIX BIOPHARMA's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. HELIX BIOPHARMA volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on HELIX BIOPHARMA correlated with the market. If Beta is less than 0 HELIX BIOPHARMA generally moves in the opposite direction as compared to the market. If HELIX BIOPHARMA Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one HELIX BIOPHARMA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of HELIX BIOPHARMA is generally in the same direction as the market. If Beta > 1 HELIX BIOPHARMA moves generally in the same direction as, but more than the movement of the benchmark.
Additional Tools for HELIX Stock Analysis
When running HELIX BIOPHARMA's price analysis, check to measure HELIX BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HELIX BIOPHARMA is operating at the current time. Most of HELIX BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of HELIX BIOPHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HELIX BIOPHARMA's price. Additionally, you may evaluate how the addition of HELIX BIOPHARMA to your portfolios can decrease your overall portfolio volatility.